Sign in
Taking people in New ZealandPhase 1

Tests Tune-401 safety in adults with chronic hepatitis B

Tests the new Tune-401 treatment for safety in adults with chronic hepatitis B.

Key facts

Who runs it
Tune Therapeutics, Inc.
Where
Auckland, New ZealandSee the siteAlso in 2 other countries, 2 sites
Trial code
Registry title
Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B
Status
Recruiting
Phase
Phase 1
People taking part
36 people, planned
Started
29 Nov 2024
Expected to end
30 Oct 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Tune-401
Record updated
6 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic hepatitis B who are already taking a nucleos(t)ide analogue medicine.

Age
18 to 75 years
Sex
Men and women can join.
Disease stage
Chronic hepatitis B infection. HBeAg can be negative or positive.
Earlier treatment
People must be taking a nucleos(t)ide analogue.
Biomarker or test result
HBeAg-negative or HBeAg-positive. Body mass index (BMI) of 18.5 kg/m² or more at screening.

Main reasons for not taking part

  • ALT/AST of 1.5 × the upper limit of normal (ULN) or more together with total bilirubin of 1.5 × ULN or more
  • Any sign or history of liver disease not caused by hepatitis B virus

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • M/F, BMI ≥ 18.5 kg/m² at screening, age 18-75, inclusive
  • Diagnosed with Chronic Hepatitis B
  • On nucleos(t)ide analogue
  • HBeAg-negative or positive

Who cannot take part

  • Participants with any evidence or history of liver disease of non-HBV etiology
  • ALT/ AST ≥ 1.5 × upper limit of normal (ULN) and total bilirubin ≥ 1. 5 × ULN
  • Other protocol defined Inclusion/Exclusion criteria may apply

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial is currently available in New Zealand.

Also in 2 other countries, 2 sites

  • New Zealand Clinical ResearchAuckland, New ZealandContact: New Zealand Clinical ResearchTaking people

About the trial

What the trial wants to find out

This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Tune-401 in adult participants with Chronic Hepatitis B.

The 2 groups in the trial

  • Tune-401 Part I : Single Ascending DoseTreatment being tested

    Epigenetic gene silencing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration

    Treatment: Tune-401

  • Tune-401 Part II :Single/Finite Multiple DoseTreatment being tested

    Epigenetic gene silencing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration

    Treatment: Tune-401

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1b Multicenter, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tune-401 in Participants With Chronic Hepatitis B Infection
Plain-language title
Tests Tune-401 safety in adults with chronic hepatitis BGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT06671093, who can take part
Record updated
6 January 2026